Farooqi Lab
@Farooqi_Lab
Followers
3K
Following
1K
Media
55
Statuses
503
Professor Sadaf Farooqi’s lab @Cambridge_Uni. We study the fundamental mechanisms controlling human energy homeostasis to identify treatments for obesity.
Cambridge, England
Joined January 2019
RT @DMM_Journal: Read our interview with #biologists100 plenary speaker, Sadaf Farooqi, discussing the fascinating insights from her work o….
0
2
0
As discussed in my accompanying Perspective (, the desire for dessert is highly conserved across species, hard-wired in the brain and brings challenges in the modern environment! (3/3).
science.org
A neural circuit in mice mediates the preference for high-sugar food after a meal
0
3
9
beta-endorphin generated by hypothalamic pomc neurons acts on mu-opioid receptors in the paraventricular thalamus to regulate this behaviour. (2/3)
1
0
0
Interesting paper in this week's issue of @ScienceMagazine ( on a neural circuit mediating preference for sweet food after a meal. (1/3).
science.org
High sugar–containing foods are readily consumed, even after meals and beyond fullness sensation (e.g., as desserts). Although reward-driven processing of palatable foods can promote overeating, the...
1
6
26
Professor Farooqi and @FRubinoMD spoke with @ScienceMagazine on @TheLancetEndo report on obesity. Is obesity a disease? Not always, new expert report says | Science | AAAS
science.org
A more scientific definition of obesity should guide decisions about weight loss treatment, researchers argue
0
4
11
Professor Farooqi spoke to the Guardian for their Friday Briefing about @TheLancetEndo report on obesity.
theguardian.com
In today’s newsletter: An international commission has called for a ‘radical overhaul’ of the way obesity is diagnosed, raising concerns about the limitations of body mass index (BMI) as a diagnostic...
0
3
8
RT @Co_Biologists: This week, we are also highlighting Sadaf Farooqi as our extraordinary biologist. She is a former Company Director and a….
0
1
0
RT @WorldObesity: 🆕 A new @TheLancetEndo report redefines obesity, distinguishing ‘pre-clinical’ (at risk) & ‘clinical’ (requiring treatmen….
bbc.co.uk
There is a risk too many people are being diagnosed as obese, with weight-loss drugs in high demand.
0
4
0
RT @ECPObesity: 🌍 A New Approach to Obesity: Moving Beyond BMI. The Lancet Commission has called for a groundbreaking shift in diagnosing o….
0
10
0
RT @TheLancetEndo: New—The Lancet Diabetes & Endocrinology Commission on: .Definition and diagnostic criteria of #clinical #obesity https:….
thelancet.com
Current BMI-based measures of obesity can both underestimate and overestimate adiposity and provide inadequate information about health at the individual level, which undermines medically-sound...
0
123
0
RT @TheLancet: Over 1 billion people live with #obesity. There is an urgent need for a universal definition & diagnosis. 🆕 A @TheLancetEnd….
0
242
0
RT @ChenLiuLab: Excited to share @Baijie_Xu’s work with @Farooqi_Lab in @ScienceTM (. Our study uncovers a molecula….
science.org
Orthopedia regulates the transcription of melanocortin 4 receptor in hypothalamic neurons, and its disruption causes obesity in mice and humans.
0
14
0
These studies pave the way for people with OTP mutations to be treated in the future. Thanks to all the team for making this happen and to our collaborators. (3 of 3).@rarediseaseuk @CamMetaboNet @IMS_MRL.@CambridgeBRC @FondationBotnar @wellcometrust.
0
0
1
Mice carrying a loss of function OTP mutation found in a child with obesity gain weight and can be treated with a licensed MC4R agonist. (2 of 3).
1
0
0
Collaborative studies with @ChenLiuLab show that Orthopedia (OTP) regulates MC4R transcription, published in Science Translational Medicine. (1 of 3).
science.org
Orthopedia regulates the transcription of melanocortin 4 receptor in hypothalamic neurons, and its disruption causes obesity in mice and humans.
1
1
14
Thanks to all the team for making this happen and to our collaborators on the trial. @rarediseaseuk @CamMetaboNet @MRL_Cam.@CambridgeBRC @FondationBotnar @wellcometrust.
0
1
3
It has been remarkable to see the impact on children we have treated, who are now normal weight and doing well at school.
1
2
3
Results have led to MHRA extending the license for this drug, so children in the UK can now be treated from age 2. This will limit the physical, mental and social impact of obesity on these children.
1
0
1
VENTURE trial shows Setmelanotide (MC4R agonist) is effective in very young children (age 2-5 yrs) with POMC, PCSK1 and LEPR deficiencies and in Bardet-Biedl syndrome. Trial results after 12 months, published in Lancet Diabetes and Endocrinology.
1
7
19
Delighted to share a Perspective published online in Cell today with my wonderful collaborator @DrYongXu1. Topic is translating research from mice to humans in Metabolic Disease.
2
8
41